polymedco

Multi-Marker Diagnostic Strategy in Emergency Medicine:

Combinatorial Approaches to Troponin, Natriuretic Peptides, and D-Dimer

Sean-Xavier Neath, MD, PhD, FACEP

November 2024

Learning objectives

- Explain the diagnostic significance of **Troponin**, **Natriuretic Peptides** (BNP/NT-proBNP), and D-dimer in differentiating between acute coronary syndrome heart failure, and thromboembolic diseases in the emergency setting.
- Interpret and integrate results from multiple biomarkers to improve diagnostic accuracy, reduce uncertainty, and optimize treatment decisions for patients presenting with overlapping symptoms, such as chest pain and dyspnea.
- Apply biomarker-driven clinical pathways in practice, utilizing evidence-based algorithms for rapid triage, diagnosis, and treatment initiation in emergency medicine.
- Describe how the use of a multi-marker diagnostic strategy can improve patient outcomes, streamline emergency department workflows, and contribute to more efficient resource utilization within healthcare institutions.

Introduction to Multi-Marker Diagnostics

Why Diagnostics Matter in Emergency Medicine:

Rapid identification of critical conditions

Guiding immediate treatment decisions

Reducing mortality and morbidity

Role of Biomarkers:

Biomarkers provide real-time insight into physiological conditions.

Multi-marker approaches improve diagnostic accuracy.

Overview of Key Biomarkers

Troponin:

- Indicates myocardial injury (heart attack)
- Highly specific for cardiac damage

Natriuretic Peptides:

- Primarily BNP and NT-proBNP
- Indicate heart failure (fluid overload, ventricular stretch)

D-dimer:

- Marker of blood clot breakdown (fibrinolysis)
- Useful in diagnosing thromboembolic events (e.g., pulmonary embolism, deep vein thrombosis)

Why Use a Multi-Marker Strategy?

Troponin:
Cardiac specificity, but limited insight into other conditions

Natriuretic Peptides:
Reflect heart failure, but may be elevated in other conditions

D-dimer:
Sensitive for clotting issues but non-specific for specific diseases

Advantages of Multi-Marker Approach:

- Combines insights into various physiological processes
- Reduces false positives/negatives by cross-checking multiple pathways
- Enhances risk stratification and guides therapy decisions

Troponin Cardiac-Specific Biomarker

Role in Emergency Medicine:

- Gold standard for diagnosing myocardial infarction (MI)
- Elevation indicates myocardial cell death

High-Sensitivity Troponin (hs-Troponin):

- Detects even minor heart injury
- Used to rule in/out acute coronary syndromes (ACS) quickly

Clinical Applications:

- Suspected heart attack: rapid triage and initiation of care

Troponin I

Troponin I (TnI) is one of three subunits of the **troponin complex**, which regulates muscle contraction in both skeletal and cardiac muscle.

Structure and Function:

- TnI binds to **actin filaments** in the absence of calcium, keeping muscle in a relaxed state.
- It works alongside **Troponin C (TnC) and Troponin T (TnT):**
  - **TnC** binds calcium, triggering a conformational change.
  - **TnI** then undergoes a structural shift, releasing inhibition on actin-myosin interaction, allowing contraction.
  - **TnT** anchors the troponin complex to tropomyosin.

Cardiac TnI (cTnI) is specific to cardiac muscle, making it an essential **biomarker for myocardial infarction (heart attack).**

Elevated cTnI levels in the blood are used to detect **cardiac damage.**

Clinical Relevance:

- **Troponin I assays** are highly sensitive tools used in the diagnosis of acute coronary syndrome (ACS).
- **cTnI's specificity** to heart tissue minimizes false positives compared to other biomarkers.

Several Generations of Cardiac Troponin Assays



Krychtiuk KA, Newby LK 2024

Annu Rev. Med. 75459-74

High-sensitivity Cardiac Troponin Assays

Definition is Analytical, Benefit is Clinical

High Sensitivity cTn Assay



Cardiac Troponin, ng/L

Contemporary cTn Assay



Cardiac Troponin, ng/mL

- **'High-Sensitivity' is an analytical term**
- Innovation = analytical; Benefit = clinical
- **hsTn assays DO NOT measure a different analyte.**

Natriuretic Peptides – BNP and NT-proBNP

Key Functions

Released by the heart in response to ventricular stretch and volume overload

Primarily used in diagnosing and assessing heart failure

BNP vs. NT-proBNP

Both are useful, but NT-proBNP has a longer half-life

Levels rise in acute heart failure, guiding treatment

Clinical Application

Helps differentiate cardiac from non-cardiac causes of breathlessness (e.g., CHF vs. COPD)

BNP vs NT-proBNP

Shared Precursor:

B-type Natriuretic Peptide (BNP) and **N-terminal proBNP (NT-proBNP)** are both derived from the same **precursor molecule**, **proBNP**.

ProBNP is secreted by the **ventricles** of the heart in response to **ventricular stretching** or increased pressure due to heart failure.

Key differences between BNP and NT-proBNP

BNP

- Biologically active
- Shorter half-life (~20 min)
- Influenced by Entresto
- Directly involved in vasodilation, natriuresis

NT-proBNP

- Inactive fragment
- Longer half-life (~60-120 min)
- Less affected by Entresto
- Diagnostic marker only

Advantages of NT-proBNP for Patients on Entresto (Sacubitril/Valsartan):

Entresto, a heart failure medication, increases **BNP levels** by inhibiting its degradation through **neprilysin inhibition**.

- However, **NT-proBNP** levels are unaffected by Entresto, as NT-proBNP is not degraded by neprilysin.
- **NT-proBNP** offers more reliable readings for **diagnosing and monitoring heart failure** in patients treated with Entresto, avoiding confusion caused by elevated BNP levels.

D-dimer –Marker for Clot Formation and Breakdown

Role in Thrombosis:

- By-product of fibrin degradation
- Elevated in thromboembolic conditions like pulmonary embolism (PE) and deep vein thrombosis (DVT)

Utility in Emergency Medicine:

- Effective in ruling out thromboembolism in low-risk patients (high negative predictive value)
- Requires clinical decision rules (e.g., Wells criteria) to interpret

Challenges:

- Non-specific elevations (e.g., infection, trauma, cancer)

Algorithm combining D-dimer value with clinical score for assessment of thromboembolic disease



Clinical Case

Patient:
55-year-old male presents with chest pain, shortness of breath

Troponin:
Elevated → suggests myocardial injury

BNP:
Elevated → suggests heart failure

D-dimer:
Normal → reduces likelihood of thromboembolism

Outcome:
Use of all three biomarkers directs clinician towards treating acute coronary syndrome with heart failure, excluding thromboembolic complications.

Integration of Biomarkers into Clinical Pathways

Chest Pain Evaluation

Troponin to assess myocardial infarction risk
D-dimer to rule out pulmonary embolism in low-risk cases

Dyspnea Evaluation

BNP/NT-proBNP to differentiate between heart failure and other causes (e.g., pneumonia, COPD)
D-dimer for ruling out thromboembolism

Developing Protocols

Combining biomarkers with clinical judgment to speed up diagnosis, reduce unnecessary testing

What are Clinical Pathways?

Structured, evidence-based protocols used to guide diagnosis and treatment.
Designed to streamline decision-making, reduce variability in care, and ensure timely interventions.
Tailored for specific conditions (e.g., chest pain, dyspnea).

Role of Biomarkers in Clinical Pathways

Biomarkers act as critical decision points within these pathways. Help categorize patients into risk groups (low, moderate, high). Allow for faster and more accurate diagnoses by highlighting specific pathophysiological processes.

Troponin in Chest Pain Evaluation Pathways

Troponin and Acute Coronary Syndrome (ACS)

Most common use in emergency settings is for chest pain triage. Elevated troponin indicates myocardial necrosis, often pointing towards an MI.

High-Sensitivity Troponin (hs-Troponin)

Provides rapid results, allowing for "rule-in" or "rule-out" of MI within hours.

Early Diagnosis

The **0/1-hour algorithm** (measure at presentation and after 1 hour) can rule in/out MI quickly.

Clinical Impact

Avoid unnecessary admission and expedite treatment in true MI cases.

Example Pathway

1.1. Patient presents with chest pain.
2.2. ECG + hs-Troponin at admission and at 1-hour mark.
3.3. **If elevated**: Begin ACS treatment (e.g., aspirin, heparin).
4.4. **If normal**: Consider non-cardiac causes and discharge if low risk.

D-dimer in Suspected Pulmonary Embolism (PE)



D-dimer's Role

Helps rule out PE in patients with low-to-moderate clinical suspicion.

High negative predictive value—if negative, highly unlikely the patient has PE.

Clinical Decision Rules (CDR)

D-dimer must be interpreted in conjunction with validated scoring systems like the **Wells Score** or **Geneva Score** to avoid over-testing.

Low-risk patients with negative D-dimer can safely be ruled out for PE without further imaging.

Example Pathway

1. Patient presents with sudden shortness of breath, chest pain.

2. Wells Score calculated.

3. If low probability + negative D-dimer → Rule out PE.

4. If high probability or elevated D-dimer → Proceed to imaging (e.g., CT pulmonary angiography).

5. Treatment initiated if positive PE confirmed.

BNP/NT-proBNP in Acute Dyspnea Evaluation

Dyspnea can have many causes (e.g., COPD, pneumonia, pulmonary embolism, heart failure).

Elevated BNP/NT-proBNP levels strongly suggest heart failure as the underlying cause.

Distinguishing Heart Failure from Other Causes:

Critical Use in Acute Settings

Rapid differentiation:
Elevated levels can point towards heart failure in a patient with acute shortness of breath.

Helps avoid unnecessary treatments for non-cardiac causes (e.g., antibiotics for suspected pneumonia).

Example Pathway

1. Patient presents with acute dyspnea.
2. BNP/NT-proBNP measured alongside clinical examination and chest x-ray.
3. **If elevated**: Consider heart failure → initiate diuretics, monitor fluids.
4. **If normal**: Rule out heart failure → explore other causes like pneumonia or PE.

Integrating Troponin and D-dimer for Chest Pain Evaluation Multifactorial Presentation:

- Some patients may present with both chest pain and risk factors for thromboembolism (e.g., recent surgery or immobilization).
- Using troponin alone may not fully assess the risk of pulmonary embolism (PE), which can mimic a heart attack.

Multifactorial Presentation/ Multimarker Strategy:

Combined Approach:

Troponin to rule out MI.
D-dimer to rule out PE in low-risk cases.

Example Pathway:

1. Patient presents with chest pain + dyspnea.
2. Perform ECG + troponin for MI, and calculate Wells
   Score for PE.
3. Measure D-dimer.
4. If troponin elevated: Treat for MI.
5. If D-dimer elevated: Investigate for PE using imaging.
6. Adjust treatment accordingly.

Integrating Troponin and D-dimer for Chest Pain Evaluation

- **Multifactorial Presentation:**

  Some patients may present with both chest pain and risk factors for thromboembolism (e.g., recent surgery or immobilization).

  Using troponin alone may not fully assess the risk of pulmonary embolism (PE), which can mimic a heart attack.

Combined Approach:

- Troponin to rule out MI.
- D-dimer to rule out PE in low-risk cases.

Example Pathway:

1. Patient presents with chest pain + dyspnea.
2. Perform ECG + troponin for MI and calculate Wells Score for PE.
3. Measure D-dimer.
4. If troponin elevated: Treat for MI.
5. If D-dimer elevated: Investigate for PE using imaging.
6. Adjust treatment accordingly.

Combining BNP and Troponin in Dyspnea and Chest Pain

Concurrent Heart Failure and Myocardial Ischemia:

Some patients with heart failure may also experience myocardial ischemia, resulting in elevated troponin and BNP levels.

Diagnostic Use:

BNP can clarify if heart failure is exacerbating ischemic symptoms, helping differentiate isolated MI from heart failure with ischemia.

Example Pathway:

1. Patient presents with dyspnea and chest pain.
2. Measure BNP for heart failure and troponin for ischemia.
3. **If both elevated**: Treat both conditions (e.g., diuretics for heart failure, anticoagulants for MI).
4. Tailor management based on biomarker results.

Biomarkers in Elderly or High-Risk Patients

Challenges in Older Populations:

Elderly patients often present with overlapping symptoms (e.g., chest pain, dyspnea) and coexisting conditions.

Biomarkers help tease apart complex clinical presentations.

Example:

A 75-year-old with chest pain and a history of heart failure and COPD.

Combined use of BNP, troponin, and D-dimer ensures more precise diagnostics.

Pathway Adaptation:

1. Measure BNP, troponin, and D-dimer based on presentation.
2. Adjust treatments for potential concurrent conditions (e.g., fluid overload, myocardial ischemia, PE).

When Biomarkers Give Conflicting Results

Interpreting Discrepant Findings

Occasionally, biomarkers might yield conflicting results (e.g., elevated BNP but normal troponin).

Requires integration of clinical context and additional tests
(e.g., echocardiography, imaging).

Example Pathway:

1. Elevated BNP, but normal troponin in a patient with dyspnea.

2. Consider heart failure without ischemia.

3. Investigate for other causes if symptoms persist despite
biomarker findings.

The Role of Imaging in Conjunction with Biomarkers

When Biomarkers Are Not Enough

Biomarkers provide valuable guidance, but imaging often confirms the diagnosis.

For example, D-dimer might indicate a thromboembolic event, but **CT angiography** is needed to confirm PE.

Example Pathway:

1. Patient presents with chest pain, D-dimer is elevated.
2. Proceed to CT pulmonary angiography if Wells score indicates moderate/high risk for PE.
3. Biomarker results streamline decision-making, avoiding unnecessary imaging.

Clinical Case Example: Complex Presentation

Case Study

Patient: 60-year-old female with chest pain, dyspnea, and recent long-haul flight.

Biomarker Results:

- Troponin: Slightly elevated
- BNP: Normal
- D-dimer: Elevated

Interpretation:

- Troponin elevation could be related to stress-induced ischemia, while D-dimer elevation suggests possible PE.
- BNP being normal rules out heart failure.

Outcome: Patient sent for CT pulmonary angiography, confirming PE. Initiated anticoagulation therapy.

Developing Comprehensive Clinical Protocols

Customizing Pathways for Specific Hospital Settings:

- Emergency departments can create specific protocols tailored to the patient population they serve.
- Incorporate biomarkers and clinical decision rules into standard pathways for common conditions.

Future Considerations:

- Adding new biomarkers (e.g., inflammatory markers) for even more comprehensive assessments.
- Potential integration of artificial intelligence (AI) to assist with interpreting biomarker combinations in real time.

Case 1:
Acute Chest Pain with Dyspnea and Leg Swelling

67-year-old male:

Presents to the Emergency Department (ED) with sudden-onset chest pain, shortness of breath, and right leg swelling for the past three days. The patient has a history of hypertension and obesity, but no known history of heart disease.

Initial Assessment

Symptoms:
Sudden chest pain, dyspnea, unilateral leg swelling (raises suspicion for a potential thromboembolic event).

Risk Factors:
Age, obesity, recent leg swelling.

Biomarkers Ordered:

Troponin: To assess for myocardial ischemia (rule out myocardial infarction).

D-dimer: To evaluate for possible pulmonary embolism (PE) or deep vein thrombosis (DVT).

BNP/NT-proBNP: To assess for heart failure as a potential cause of dyspnea.

Biomarker Results:

Troponin: Slightly elevated (suggesting some degree of myocardial injury or ischemia, though unclear if from acute coronary syndrome).

D-dimer: Elevated (indicating possible thromboembolism, requires further imaging).

BNP: Normal (suggesting no evidence of acute heart failure).

Case 1 (cont'd):
Acute Chest Pain with Dyspnea and Leg Swelling

Interpretation and Management

Troponin Elevation: Suggests possible ischemia, but unclear whether it is the primary issue.

Elevated D-dimer: Suggests possible pulmonary embolism or deep vein thrombosis.

Normal BNP: Makes acute heart failure unlikely.

Follow-up Tests:

Based on the elevated D-dimer, a **CT pulmonary angiogram (CTPA)** is performed, revealing a large pulmonary embolism (PE).

Troponin elevation is attributed to right ventricular strain from the pulmonary embolism rather than an acute coronary event.

Outcome: The patient is treated with anticoagulants for the pulmonary embolism. The myocardial strain is monitored, but no immediate coronary intervention is required as the primary diagnosis is PE.

Case 2:

Elderly Female with Chest Pain, Syncope, and Fatigue

82-Year-Old Elderly female:

With a history of hypertension, heart failure, and type 2 diabetes presents to the ED after experiencing chest pain and syncope while climbing stairs. She has been feeling fatigued and has had swelling in her legs over the past week.

Initial Assessment

Symptoms:
Chest pain, syncope, fatigue, and leg swelling.

Risk Factors:
Advanced age, history of heart failure, hypertension, and diabetes.

Biomarkers Ordered:

Troponin: To assess for myocardial infarction or ischemia.

BNP/NT-proBNP: To assess for heart failure exacerbation.

D-dimer: To rule out pulmonary embolism, especially in light of syncope and leg swelling.

Biomarker Results:

Troponin: Elevated, suggesting myocardial injury.

BNP: Significantly elevated, indicating worsening heart failure.

D-dimer: Mildly elevated, but given the patient's risk factors (age, heart failure), a clinical decision rule suggests this is unlikely to represent PE.

Case 2 (cont'd): **Elderly Female with Chest Pain, Syncope, and Fatigue**

Interpretation and Management:

Elevated Troponin: Likely indicates a non-ST elevation myocardial infarction (NSTEMI) or myocardial ischemia secondary to the worsening heart failure.

Elevated BNP: Confirms that the patient is experiencing an exacerbation of chronic heart failure.

D-dimer Elevation: Given the overall clinical context and decision rule (Wells or Geneva Score), the slightly elevated D-dimer is interpreted cautiously, and the patient does not immediately require imaging for PE.

Treatment:

The patient is diagnosed with an acute coronary syndrome (NSTEMI) and heart failure exacerbation. She is started on **antiplatelet therapy**, **beta-blockers**, **ACE inhibitors**, and **diuretics**.

Cardiac catheterization is considered to evaluate for coronary artery disease, while the heart failure is managed with medication adjustments.

Outcome:

The patient's symptoms improve with appropriate management of both the heart failure and the myocardial ischemia. No evidence of pulmonary embolism is found, and she is discharged with close outpatient follow-up.

Case 3:
Shortness of Breath and Cough in a Middle-Aged Smoker

55-year-old male:

A history of smoking (40 pack-years) presents to the ED with progressive shortness of breath and a productive cough over the past week. He denies chest pain but has a history of COPD. There is concern for heart failure or pulmonary embolism.

Initial Assessment

Symptoms:

Shortness of breath, cough, and fatigue.

Risk Factors:

Heavy smoking history, possible underlying lung disease, and sedentary lifestyle.

Biomarkers Ordered:

Troponin: To rule out any ischemic cause of the shortness of breath.

BNP: To assess whether heart failure is contributing to the dyspnea.

D-dimer: To evaluate for the possibility of a pulmonary embolism.

Biomarker Results:

Troponin: Normal (no myocardial ischemia detected).

BNP: Slightly elevated (borderline heart failure; requires further workup to confirm or exclude).

D-dimer: Elevated (possible thromboembolism; requires imaging to confirm).

Case 3 (cont'd): Shortness of Breath and Cough in a Middle-Aged Smoker

Interpretation and Management:

Normal Troponin: No evidence of myocardial infarction or ischemia, so cardiac causes of the dyspnea are less likely.

Slightly Elevated BNP: Could suggest a mild degree of heart failure, but not definitive; may also be elevated due to lung pathology (e.g., COPD).

Elevated D-dimer: Raises suspicion for pulmonary embolism, especially in the context of recent immobility and smoking history.

Follow-up Tests:

A **CT pulmonary angiogram (CTPA)** is performed, which reveals a **small pulmonary embolism** in the right lung.

The slightly elevated BNP is attributed to increased strain on the heart due to COPD and the PE.

Outcome:

The patient is treated with anticoagulation for the pulmonary embolism and receives additional management for his COPD. He is discharged with instructions for smoking cessation and follow-up for both pulmonary and cardiac evaluation.

Case 4:
Young Woman with Post-Surgical Complications

32-year-old woman:
Presents to the ED with chest discomfort and shortness of breath one week after knee surgery. She reports that the symptoms have progressively worsened over the past 48 hours.

Initial Assessment

Symptoms:
Chest pain, shortness of breath, post-surgical recovery (increased risk for venous thromboembolism).

Risk Factors:
Recent surgery (knee), immobilization.

Biomarkers Ordered:

Troponin: To evaluate for possible myocardial infarction.

D-dimer: To assess for pulmonary embolism given her post-surgical status.

BNP: To evaluate for possible heart failure (less likely, but to rule out).

Biomarker Results:

Troponin: Normal (no myocardial injury).

D-dimer: Elevated (raises suspicion of venous thromboembolism).

BNP: Normal (heart failure not suspected).

Case 4 (cont'd): Young Woman with Post-Surgical Complications

Interpretation and Management:

Normal Troponin:
No evidence of myocardial infarction or cardiac ischemia.

Elevated D-dimer:
Suggests a high likelihood of a pulmonary embolism, especially given the recent surgery and immobilization.

Normal BNP: Indicates that heart failure is not the cause of the dyspnea.

Follow-up Tests:

CT pulmonary angiogram confirms a large pulmonary embolism in the left lung.

The patient is started on anticoagulation therapy and monitored closely for further complications.

Outcome:

The patient's symptoms improve with anticoagulation, and she is advised to continue treatment for several months. Physical therapy is initiated to mobilize her following knee surgery.

Summary and Conclusion

Key Takeaways:

- Biomarkers like troponin, BNP, and D-dimer provide essential insights in emergency medicine.
- Multi-marker strategies improve diagnostic precision and guide timely, appropriate interventions.
- Clinically integrated pathways streamline the use of these biomarkers, ensuring faster diagnosis and better patient outcomes.

Future of Biomarkers:

- Personalized medicine and AI will continue to enhance diagnostic accuracy and reduce diagnostic uncertainty.

Bibliography

1. Thygesen, K., Alpert, J. S., & Jaffe, A. S. (2018). Fourth universal definition of myocardial infarction (2018). *Journal of the American College of Cardiology*, 72(18), 2231-2264.

   A comprehensive guide to the diagnosis of myocardial infarction, including the role of Troponin in emergency settings.

2. Januzzi, J. L., van Kimmenade, R., & Lainchbury, J. (2006). NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. *European Heart Journal*, 27(3), 330-337.

   Discusses the use of natriuretic peptides (BNP, NT-proBNP) in diagnosing and managing acute heart failure in emergency situations.

3. Righini, M., Van Es, J., Den Exter, P. L., et al. (2014). Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: The ADJUST-PE study. *JAMA*, 311(11), 1117-1124.

   This study explains the use of D-dimer in ruling out pulmonary embolism, including adjustments for age in clinical practice.

4. Kavsak, P. A., Newman, A. M., Ko, D. T., & Jaffe, A. S. (2017). High-sensitivity cardiac troponin for the rapid diagnosis of acute coronary syndromes. *Journal of the American College of Cardiology*, 70(3), 290-291.

   Provides insights into the utility of high-sensitivity cardiac troponin in the rapid diagnosis of acute coronary syndrome.

5. Konstantinides, S. V., Meyer, G., Becattini, C., et al. (2019). 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *European Heart Journal*, 41(4), 543-603.

   The latest European Society of Cardiology (ESC) guidelines on the diagnosis and treatment of pulmonary embolism, emphasizing D-dimer use.

Bibliography

6. Mueller, C., Giannitsis, E., Christ, M., et al. (2012). Multinational, multicenter study of the use of high-sensitivity cardiac troponin T in patients with suspected acute coronary syndromes: Results of the TRAPID-AMI study (High-Sensitivity Cardiac Troponin T Assay for Rapid Rule-out of Acute Myocardial Infarction). *Circulation*, 126(25), 3108-3116.

   Investigates the use of high-sensitivity troponin T to rapidly rule out myocardial infarction in emergency settings.

7. McGee, S., & Hirschmann, J. (2008). Use of D-dimer in the diagnosis of venous thromboembolism. *BMJ*, 336(7648), 1361-1364.

   Reviews the application of D-dimer in diagnosing venous thromboembolism and its limitations in emergency care.

8. Januzzi, J. L. Jr., & Jarolim, P. (2013). Natriuretic peptide testing for heart failure. *Circulation*, 127(4), 450-455.

   This article details the role of BNP and NT-proBNP in the diagnosis and prognosis of heart failure.

9. Peacock, W. F., & De Marco, T. (2003). Cardiac biomarkers in acute decompensated heart failure. *Journal of the American College of Cardiology*, 41(12), 104-110.

   Discusses the use of biomarkers in diagnosing acute heart failure, particularly focusing on BNP and NT-proBNP.

10. Wells, P. S., Anderson, D. R., & Rodger, M. (2003). Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. *The New England Journal of Medicine*, 349(13), 1227-1235.

    A foundational study on the role of D-dimer in the evaluation of deep vein thrombosis.